ATE454382T1 - Verbindungen mit selektiverinhibierender wirkung für gsk3 - Google Patents

Verbindungen mit selektiverinhibierender wirkung für gsk3

Info

Publication number: ATE454382T1
Authority: AT; Austria
Prior art keywords: compounds; alkylnr; gsk3; alkylc; solvate
Prior art date: 2002-12-17

Application number

AT03781204T

Other languages

English (en)

Inventor

Stefan Berg

Sven Hellberg

Peter Soederman

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-17

Filing date

2003-12-15

Publication date

2010-01-15

2003-12-15 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2010-01-15 Application granted granted Critical

2010-01-15 Publication of ATE454382T1 publication Critical patent/ATE454382T1/de

Links

150000001875 compounds Chemical class 0.000 title abstract 4
102000001267 GSK3 Human genes 0.000 title 1
108060006662 GSK3 Proteins 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 title 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
239000012453 solvate Substances 0.000 abstract 2
125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
125000002877 alkyl aryl group Chemical group 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
239000012458 free base Substances 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
125000005842 heteroatom Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Immunology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Gynecology & Obstetrics (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Orthopedic Medicine & Surgery (AREA)

AT03781204T 2002-12-17 2003-12-15 Verbindungen mit selektiverinhibierender wirkung für gsk3 ATE454382T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE0203754A SE0203754D0 (sv)	2002-12-17	2002-12-17	New compounds
PCT/SE2003/001955 WO2004055005A1 (en)	2002-12-17	2003-12-15	Novel compounds having selective inhibiting effect at gsk3

Publications (1)

Publication Number	Publication Date
ATE454382T1 true ATE454382T1 (de)	2010-01-15

Family

ID=20289907

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03781204T ATE454382T1 (de)	2002-12-17	2003-12-15	Verbindungen mit selektiverinhibierender wirkung für gsk3

Country Status (18)

Country	Link
US (2)	US7585853B2 (de)
EP (2)	EP1575938B1 (de)
JP (1)	JP4674088B2 (de)
KR (1)	KR101110457B1 (de)
CN (1)	CN100351250C (de)
AT (1)	ATE454382T1 (de)
AU (1)	AU2003287135B2 (de)
BR (1)	BR0317294A (de)
CA (1)	CA2508042C (de)
DE (1)	DE60330910D1 (de)
ES (1)	ES2337682T3 (de)
IL (1)	IL169016A (de)
MX (1)	MXPA05006243A (de)
NO (1)	NO331495B1 (de)
NZ (1)	NZ540449A (de)
SE (1)	SE0203754D0 (de)
WO (1)	WO2004055005A1 (de)
ZA (1)	ZA200504617B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7704995B2 (en)	2002-05-03	2010-04-27	Exelixis, Inc.	Protein kinase modulators and methods of use
SE0203753D0 (sv) *	2002-12-17	2002-12-17	Astrazeneca Ab	New compounds
SE0203752D0 (sv) *	2002-12-17	2002-12-17	Astrazeneca Ab	New compounds
CA2577937C (en) *	2004-08-26	2010-12-21	Pfizer Inc.	Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
JP4242911B2 (ja)	2004-08-26	2009-03-25	ファイザー・インク	プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物
WO2008156174A1 (ja) *	2007-06-21	2008-12-24	Taisho Pharmaceutical Co., Ltd.	ピラジンアミド化合物
UA103319C2 (en)	2008-05-06	2013-10-10	Глаксосмитклайн Ллк	Thiazole- and oxazole-benzene sulfonamide compounds
EP2138485A1 (de) *	2008-06-26	2009-12-30	sanofi-aventis	Substituierte N-Oxid-Pyrazin-Derivate
KR101712576B1 (ko)	2008-11-10	2017-03-06	버텍스 파마슈티칼스 인코포레이티드	Ａｔｒ 키나제의 억제제로서 유용한 화합물
PL3354650T3 (pl)	2008-12-19	2022-06-13	Vertex Pharmaceuticals Incorporated	Związki przydatne jako inhibitory kinazy atr
UY33027A (es) *	2009-11-13	2011-06-30	Astrazeneca Ab	Pirazina sustituida con oxazolo[4,5-c]piridina
US8198285B2 (en) *	2010-01-19	2012-06-12	Astrazeneca Ab	Pyrazine derivatives
US9096584B2 (en)	2010-05-12	2015-08-04	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
JP2013526538A (ja)	2010-05-12	2013-06-24	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｒキナーゼ阻害剤として有用な化合物
JP2013526540A (ja)	2010-05-12	2013-06-24	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｒキナーゼ阻害剤として有用な化合物
JP5836367B2 (ja)	2010-05-12	2015-12-24	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ａｔｒキナーゼ阻害剤として有用な化合物
US8962631B2 (en)	2010-05-12	2015-02-24	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
WO2011143423A2 (en)	2010-05-12	2011-11-17	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
JP2013529643A (ja)	2010-06-23	2013-07-22	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｒキナーゼ阻害剤として有用なピロロピラジン誘導体
CA2832100A1 (en)	2011-04-05	2012-10-11	Vertex Pharmaceuticals Incorporated	Aminopyrazine compounds useful as inhibitors of tra kinase
LT2714677T (lt)	2011-05-23	2018-12-10	Merck Patent Gmbh	Piridino ir pirazino dariniai
PL2714668T3 (pl)	2011-05-23	2017-06-30	Merck Patent Gmbh	Pochodne tiazolowe
JP2014522818A (ja)	2011-06-22	2014-09-08	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｒキナーゼ阻害剤として有用な化合物
WO2012178123A1 (en)	2011-06-22	2012-12-27	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
WO2012178125A1 (en)	2011-06-22	2012-12-27	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
DE102011112978A1 (de)	2011-09-09	2013-03-14	Merck Patent Gmbh	Benzonitrilderivate
US8765751B2 (en)	2011-09-30	2014-07-01	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
AU2012315384B2 (en)	2011-09-30	2017-08-10	Vertex Pharmaceuticals Incorporated	Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors
US8853217B2 (en)	2011-09-30	2014-10-07	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
RU2018147217A (ru)	2011-09-30	2019-01-18	Вертекс Фармасьютикалз Инкорпорейтед	Способы получения соединений, которые можно использовать в качестве ингибиторов киназы atr
IN2014KN00943A (de)	2011-09-30	2015-08-21	Vertex Pharma
WO2013071090A1 (en)	2011-11-09	2013-05-16	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
EP2776421A1 (de)	2011-11-09	2014-09-17	Vertex Pharmaceuticals Incorporated	Als atr-kinasehemmer nützliche verbindungen
US8841450B2 (en)	2011-11-09	2014-09-23	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
US8841449B2 (en)	2011-11-09	2014-09-23	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
EP2776429A1 (de)	2011-11-09	2014-09-17	Vertex Pharmaceuticals Incorporated	Als atr-kinaseinhibitoren nützliche verbindungen
DE102011119127A1 (de)	2011-11-22	2013-05-23	Merck Patent Gmbh	3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
CN104093722B (zh)	2012-02-09	2016-07-27	默克专利股份公司	作为TBK1和IKK抑制剂的呋喃并[3,2-b]-和噻吩并[3,2-b]吡啶衍生物
CN104582795B (zh)	2012-04-05	2018-04-20	沃泰克斯药物股份有限公司	可用作atr激酶抑制剂的化合物及其组合疗法
DK2904406T3 (en)	2012-10-04	2018-06-18	Vertex Pharma	METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
US8912198B2 (en)	2012-10-16	2014-12-16	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
LT3418281T (lt)	2012-12-07	2021-01-11	Vertex Pharmaceuticals Inc.	Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
WO2014143240A1 (en)	2013-03-15	2014-09-18	Vertex Pharmaceuticals Incorporated	Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
HUE046727T2 (hu)	2013-12-06	2020-03-30	Vertex Pharma	Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
WO2015155738A2 (en)	2014-04-09	2015-10-15	Christopher Rudd	Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
ES2777608T3 (es)	2014-06-05	2020-08-05	Vertex Pharma	Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
US11179394B2 (en)	2014-06-17	2021-11-23	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of Chk1 and ATR inhibitors
JO3589B1 (ar)	2014-08-06	2020-07-05	Novartis Ag	مثبطات كيناز البروتين c وطرق استخداماتها
AU2015350315B2 (en) *	2014-11-18	2020-06-25	Merck Sharp & Dohme Corp.	Aminopyrazine compounds with A2A antagonist properties
US11464774B2 (en)	2015-09-30	2022-10-11	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MA26473A1 (fr) *	1997-03-01	2004-12-20	Glaxo Group Ltd	Composes pharmacologiquement actifs.
ATE307121T1 (de) *	2000-02-16	2005-11-15	Neurogen Corp	Substituierte arylpyrazine
WO2001066531A1 (de) *	2000-03-07	2001-09-13	Aventis Pharma Deutschland Gmbh	Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one (und) ihre verwendung zur hemmung der hormonsensitiven lipase
AR029489A1 (es) *	2000-03-10	2003-07-02	Euro Celtique Sa	Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
MXPA03010232A (es) *	2001-05-11	2004-03-16	Biovitrum Ab	Compuestos de arilsulfonamida, para el tratamiento de la obesidad, de la diabetes tipo ii y de trastornos del sistema nervioso central.
SE0102439D0 (sv) *	2001-07-05	2001-07-05	Astrazeneca Ab	New compounds
SE0102438D0 (sv) *	2001-07-05	2001-07-05	Astrazeneca Ab	New compounds
JP2003081937A (ja) *	2001-09-07	2003-03-19	Bayer Ag	ベンゼンスルホンアミド誘導体
SE0203752D0 (sv) *	2002-12-17	2002-12-17	Astrazeneca Ab	New compounds

2002
- 2002-12-17 SE SE0203754A patent/SE0203754D0/xx unknown
2003
- 2003-12-15 JP JP2004560223A patent/JP4674088B2/ja not_active Expired - Fee Related
- 2003-12-15 US US10/539,543 patent/US7585853B2/en not_active Expired - Fee Related
- 2003-12-15 WO PCT/SE2003/001955 patent/WO2004055005A1/en not_active Ceased
- 2003-12-15 KR KR1020057011137A patent/KR101110457B1/ko not_active Expired - Fee Related
- 2003-12-15 EP EP03781204A patent/EP1575938B1/de not_active Expired - Lifetime
- 2003-12-15 NZ NZ540449A patent/NZ540449A/en not_active IP Right Cessation
- 2003-12-15 BR BR0317294-5A patent/BR0317294A/pt not_active IP Right Cessation
- 2003-12-15 AT AT03781204T patent/ATE454382T1/de not_active IP Right Cessation
- 2003-12-15 DE DE60330910T patent/DE60330910D1/de not_active Expired - Lifetime
- 2003-12-15 ES ES03781204T patent/ES2337682T3/es not_active Expired - Lifetime
- 2003-12-15 CA CA2508042A patent/CA2508042C/en not_active Expired - Fee Related
- 2003-12-15 MX MXPA05006243A patent/MXPA05006243A/es active IP Right Grant
- 2003-12-15 AU AU2003287135A patent/AU2003287135B2/en not_active Ceased
- 2003-12-15 CN CNB2003801066631A patent/CN100351250C/zh not_active Expired - Fee Related
- 2003-12-15 EP EP09180635A patent/EP2161265A3/de not_active Withdrawn
2005
- 2005-06-06 IL IL169016A patent/IL169016A/en not_active IP Right Cessation
- 2005-07-15 NO NO20053460A patent/NO331495B1/no not_active IP Right Cessation
2006
- 2006-01-16 ZA ZA200504617A patent/ZA200504617B/en unknown
2009
- 2009-08-21 US US12/545,213 patent/US20100075989A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1575938A1 (de)	2005-09-21
KR101110457B1 (ko)	2012-02-17
AU2003287135A1 (en)	2004-07-09
SE0203754D0 (sv)	2002-12-17
NO331495B1 (no)	2012-01-16
US20060116362A1 (en)	2006-06-01
US7585853B2 (en)	2009-09-08
MXPA05006243A (es)	2005-08-19
CA2508042A1 (en)	2004-07-01
AU2003287135B2 (en)	2007-01-25
CA2508042C (en)	2012-01-10
EP2161265A3 (de)	2010-06-02
JP2006513180A (ja)	2006-04-20
KR20050084363A (ko)	2005-08-26
IL169016A (en)	2013-08-29
CN1729185A (zh)	2006-02-01
EP1575938B1 (de)	2010-01-06
NZ540449A (en)	2008-02-29
US20100075989A1 (en)	2010-03-25
ES2337682T3 (es)	2010-04-28
HK1080856A1 (en)	2006-05-04
WO2004055005A8 (en)	2005-06-30
JP4674088B2 (ja)	2011-04-20
CN100351250C (zh)	2007-11-28
ZA200504617B (en)	2006-03-29
WO2004055005A1 (en)	2004-07-01
EP2161265A2 (de)	2010-03-10
DE60330910D1 (de)	2010-02-25
BR0317294A (pt)	2005-11-08
NO20053460L (no)	2005-08-12

Legal Events

Date	Code	Title	Description
2010-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60330910D1 (de)	2010-02-25	Verbindungen mit selektiverinhibierender wirkung für gsk3
AR034268A1 (es)	2004-02-18	Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion
NZ514234A (en)	2004-02-27	N-cyanomethylamides as protease inhibitors
NO20025641D0 (no)	2002-11-22	Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
YU31303A (sh)	2006-05-25	Jedinjenja imidazola sa pripojenim arilom ili heteroarilom kao anti-inflamatorni i analgetički agensi
MXPA03007249A (es)	2005-02-14	Compuestos triazolo como inhibidores de mmp.
ES2055860T3 (es)	1994-09-01	Derivados 2-aminopirimidinona.
GEP20063890B (en)	2006-08-10	Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
UY27368A1 (es)	2003-01-31	Nuevos compuestos
AR032781A1 (es)	2003-11-26	Amidas ariladas de acidos furan- y tiofencarboxilicos, composiciones farmaceuticas, su utilizacion para la preparacion de medicamento como tambien las composiciones farmaceuticas que las contienen
NO20045486L (no)	2005-02-02	Nye forbindelser og deres anvendelse
MXPA04000456A (es)	2004-03-18	Analogos de prostaglandina como agonistas del receptor ep4.
NO20025640D0 (no)	2002-11-22	Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
NO20015172L (no)	2002-01-23	1-metyl-erytromycin-derivater
SE0100569D0 (sv)	2001-02-20	New compounds
DZ1694A1 (fr)	2002-02-17	"n-(2-Aminoethyl)-benzothialozones".
AU8799201A (en)	2002-04-08	Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases
GEP20053505B (en)	2005-05-10	Diphenyl Ether Compounds Useful in Therapy
SE0201194D0 (sv)	2002-04-19	New compounds
NO911525L (no)	1991-10-21	Nye 2,9-disubstituerte-4h-pyrido(1,2-a)pyrimidin-4-oner.
SE0102440D0 (sv)	2001-07-05	New compound
MXPA04005313A (es)	2004-09-13	Derivados de aminotetralin como antagonistas del receptor muscarinico.
HUP0203275A2 (hu)	2003-01-28	1-(Gyűrűs amino)-alkilciklohexán-származékok, ezeket tartalmazó görcsoldó hatású gyógyszerkészítmények, valamint ezek alkalmazása
NO20060383L (no)	2006-01-24	Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister
UY27324A1 (es)	2003-02-28	Nuevas sales de napsilato i